Real-World Discontinuations of Ocrelizumab in MS Comparable to Pivotal Trials 

Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in pivotal clinical trials among patients with different types of multiple sclerosis (MS).